MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.
暂无分享,去创建一个
Ananya Choudhury | D. Bishop | R. Bristow | S. Bhattarai | A. Kiltie | M. Churchman | C. Taylor | M. Knowles | J. Bentley | A. Choudhury | M. Teo | F. Elliott | Louisa Nelson | S. Chilka | C. Johnston | J. Lowery | P. Harnden | Robert G Bristow | Johanne Bentley | Michael Churchman | D Timothy Bishop | Faye Elliott | Margaret A Knowles | Anne E Kiltie | Patricia Harnden | Louisa D Nelson | Mark T W Teo | Sameer Chilka | Selina Bhattarai | Colin F Johnston | Johanna Lowery | Claire F Taylor | Claire F. Taylor
[1] J. Overgaard,et al. The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[2] P. Hall,et al. Assessing p53 in clinical contexts: unlearned lessons and new perspectives , 2006, The Journal of pathology.
[3] Thierry Soussi,et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation , 1996, Nucleic Acids Res..
[4] J. Bartek,et al. The DNA-damage response in human biology and disease , 2009, Nature.
[5] A. Hart,et al. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. , 2001, International journal of radiation oncology, biology, physics.
[6] R. Bergström,et al. p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy. , 1995, European urology.
[7] S. Fosså,et al. p53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder , 2001, BJU international.
[8] I. Tannock,et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. , 2007, Urologic oncology.
[9] C. Rödel,et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. , 2000, International journal of radiation oncology, biology, physics.
[10] D. Lane,et al. P53 abnormalities and outcomes in colorectal cancer: a systematic review , 2005, British Journal of Cancer.
[11] A. Gown. Current issues in ER and HER2 testing by IHC in breast cancer , 2008, Modern Pathology.
[12] J. Ribeiro,et al. Relationship between radiation response and p53 status in human bladder cancer cells. , 1997, International journal of radiation biology.
[13] Samantha Sharpe,et al. Cancer Research UK , 2002, Nature Cell Biology.
[14] M. Lavin. ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks , 2007, Oncogene.
[15] A. Kiltie,et al. APE1 and XRCC1 Protein Expression Levels Predict Cancer-Specific Survival Following Radical Radiotherapy in Bladder Cancer , 2005, Clinical Cancer Research.
[16] H. Liber,et al. NBS1 knockdown by small interfering RNA increases ionizing radiation mutagenesis and telomere association in human cells. , 2005, Cancer Research.
[17] G. Bussolati,et al. Technical pitfalls potentially affecting diagnoses in immunohistochemistry , 2008, Journal of Clinical Pathology.
[18] Xiao-Feng Sun,et al. ATM expression in rectal cancers with or without preoperative radiotherapy. , 2005, Oncology reports.
[19] L. Skoog,et al. Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. , 2007, International journal of radiation oncology, biology, physics.
[20] M. Suntharalingam,et al. Radiosensitization of head/neck squamous cell carcinoma by adenovirus-mediated expression of the Nbs1 protein. , 2007, International journal of radiation oncology, biology, physics.
[21] R. Huddart,et al. SPARE: A qualitative study investigating randomization barriers in a Selective Bladder Preservation trial (SBP) (ISCRCTN: 61126465). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Mellon,et al. Improving and predicting radiosensitivity in muscle invasive bladder cancer. , 2003, The Journal of urology.
[23] I. N. Reid,et al. A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[24] A. Kiltie,et al. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. , 2008, International journal of radiation oncology, biology, physics.
[25] D. Neal,et al. Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. , 2001, International journal of radiation oncology, biology, physics.
[26] I. Runnebaum,et al. Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas , 2005, International Journal of Gynecologic Cancer.
[27] H. Tauchi,et al. Dancing on damaged chromatin: functions of ATM and the RAD50/MRE11/NBS1 complex in cellular responses to DNA damage. , 2008, Journal of radiation research.
[28] A. Gotoh,et al. Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type-p53 but not in p53-mutated bladder cancer cells , 2003, Urological Research.
[29] M. Oren,et al. Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.
[30] M. Olivier,et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.
[31] C. Cordon-Cardo. p53 and RB: simple interesting correlates or tumor markers of critical predictive nature? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] S. Fosså,et al. Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: an immunohistochemical study. , 1998, British journal of urology.
[33] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.
[34] B. Czerniak,et al. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. , 1996, Urology.
[35] D. Hwang,et al. Gastrosplenic fistula from Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Alessandra Viel,et al. Human MRE11 is inactivated in mismatch repair‐deficient cancers , 2002, EMBO reports.
[37] G. Capellá,et al. p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined‐modality approach , 2004, Cancer.
[38] G. Kerr,et al. Radical radiotherapy and salvage cystectomy as the primary management of transitional cell carcinoma of the bladder. Results following the introduction of a CT planning technique. , 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).